Project CT-03 recommended for funding in the EIC Accelerator competition

Current report no. 12/2025

Drafting date: 17.02.2025

Subject: Project CT-03 recommended for funding in the EIC Accelerator competition

Legal basis: Article 17(1) MAR - confidential information.

The Management Board of Captor Therapeutics S.A., based in Wroclaw, Poland (the “Company”) informs that the Company has been selected for the preparation stage of the grant agreement for the CT-03 project “A First-in-Class MCL-1 degrader to promote apoptosis in therapy-resistant liquid and solid tumours” in the EIC Accelerator competition under Horizon Europe.

The project aims to demonstrate safety and lack of cardiotoxicity in humans in a Phase Ia/Ib clinical trial in patients with acute myeloid leukaemia (AML).

The requested total funding for the project is €7.8 million. The funding includes €2.5 million in grant financing and a possible equity investment of European Investment Bank in the amount of €5.3 million. If a suitable grant agreement is concluded and the project is carried out, the grant awarded may restrict the use of the Company's own funds for financing of the project.

The Company will announce the conclusion of the relevant grant agreement and/or further steps in process as required by law.